ALX Oncology Holdings Inc. announced the pricing of an underwritten offering of common stock and pre-funded warrants, expecting to raise approximately $150 million. The financing is led by new investors RA Capital Management and TCGX. ALX Oncology plans to use the proceeds for clinical development and general corporate purposes. The offering is expected to close on or about February 2, 2026, with Piper Sandler, UBS Investment Bank, and Wells Fargo Securities as joint lead book-running managers. The securities are offered pursuant to a shelf registration statement with the SEC. ALX Oncology is a clinical-stage biotechnology company focused on developing cancer therapies like evorpacept and ALX2004.

Read more at GlobeNewswire: ALX Oncology Announces Pricing of Underwritten Offering